University of Cambridge > > euroscicon > Beating Malaria – London 2014

Beating Malaria – London 2014

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Speaker to be confirmed.

Three day malaria conference series

This three day event will discuss aspects of Malaria control, infection and treatment in an informal academic setting. This year there are three main topics for discussion

Vector Control: Research, Economics and Policy Immunology and Vaccination Malaria Drug Development and Resistance Control

With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Malaria.

This event has CPD accreditation and an open oral and poster session.

Abstracts can be submitted on any subject related to Malaria

The Deadline for abstract submissions for oral presentation is April 10th 2014. Abstracts for poster presentation only can be submitted up to two weeks before the event . You can download the instructions for authors at Who Should Attend: Member of Research Institutions, Government bodies, NGOs, International Organizations and Academies and Pharmaceutical R and D

Program Outline Day 1: Vector Control: Research, Economics and Policy The WHO estimations on the burden of malaria do not fully reflect the availability of new tools to fight the diseases nor the multiplicity of parasitological, epidemiology and treatment research- as well as the new thinking on financing- that have been taken place in the last decade. In fact 219 million cases of malaria occur every year around the world and 660.000 people still die – mainly in children under the age of 5. Moreover, it is evident that current funding levels do not allow for full implementation of the newest and most effective interventions globally: The Roll Back Malaria Partnership estimates that an annual funding gap of about $2.8 billion will need to be filled in order to to reduce its incidence by 75% and malaria deaths to zero by 2015. This session aims at understanding the scientific, economic and political implications behind the opportunities and hurdles to stop this killing disease and to achieve the Millennium Development Goals targets.

Day 2: Immunology and Vaccination This session will discuss the mechanisms of immunity and immunopathology in order to facilitate vaccine design and the identification of additional therapies for treatment of severe malaria. There will be plenty of opportunities for debate and networking.

Day 3: Drug Development and Resistance Control The prevention of anti-malarial drug resistance is of enormous public health importance. It can be assumed that no therapy currently under development or to be developed in the foreseeable future will be totally protective against malaria. This session will discuss the development of new treatments for malaria together with the use of current drugs to limit, insofar as it is possible, any further development of resistance. There will be plenty of opportunity for delegates to present their work and network in an informal atmosphere, with a lot of time given for discussion and debate.

Talks include Possible new controlling measures for the pyrethroid-resistant malaria vectors, Dr Hitoshi Kawada, Associate Professor, Institute of Tropical Medicine, Nagasaki University, Japan

Development of enantiomerically pure aminoalcohol quinoline derivatives to improve their antimalarial efficiency and assessment of their activity against Plasmodium falciparum in combination with dihydroartemisinin, Dr Catherine Mullié, Assistant Professor, Faculté de Pharmacie, Université de Picardie Jules Verne, France

Fast tracking antimalarial drug discovery through repositioning, Nirmalan Niroshini, University of Salford, Manchester, UK

TAntibody longevity to malaria vaccine candidate antigens in immuno-epidemiology studies. Dr Freya Fowkes, Head of Malaria and Infectious Disease Epidemiology, Burnet Institute, Australia

Availability and Affordability of Arthemisinin Combination Therapies: do the subsidies work?, Miss Giulia Boselli, Global Health Specialist- Consultant, UK

Malaria control in coastal areas – special research and policy needs, Professor Ranjan Ramasamy, Visiting Professor, University of Jaffna, Sri Lanka

Antimalarials that improve immune response, Professor José M. Bautista, Complutense University of Madrid, Madrid, Spain

Natural products as a source of new drugs and/or herbal treatments for Malaria, Dr Colin Wright, Reader in Pharmacognosy, Bradford School of Pharmacy, University of Bradford, UK

Malaria control: the nutraceutical potential of natural cocoa powder, Professor Frederick Addai, Academic Researcher, University of Ghana Medical School, Ghana

Citrulline: A novel therapeutic for the cerebral malaria. Dr Irene Gramaglia, Associate Professor, La Jolla Infectious Disease Institute, USA

Platelets do not kill blood-stage Plasmodium parasites but function in experimental cerebral malaria pathogenesis. Dr Joyce M. Velez, Post-doctoral fellow, La Jolla Infectious Disease Institute, USA

Additional confirmed speakers include Dr Britta Urban, Liverpool School of Tropical Medicine, United Kingdom Dr Pierre Guermonprez, Center for Molecular and Cellular Biology of Inflammation, King’s College London, United Kingdom Dr Glenn McConkey, Senior Lecturer, School of Biology, University of Leeds, UK Dr Mohga Kamal-Yanni, Senior health & HIV policy advisor, Oxfam GB Mr Aditya Jha, Centre for Cellular and Molecular Biology, India Dr Bhargavi Rao, Honorary Clinical Research Fellow, Imperial College London, UK Professor Andrew Taylor-Robinson, Professor of Immunology/Haematology & Deputy Dean Research | School of Medical & Applied Sciences CQ University Rockhampton, Queensland, Australia

Keywords: Malaria,Vector,Biological Control, chemical control,Insecticide, tsetse flies, Habitat Control, LLIN , Anopheles, pyrethroid, resistance, repellent, Anopheles vectors, Environmental change, Malaria, Salinity tolerance, Sea level rise, malaria, reseach, policy, financing, medicines, Vaccine,Antibody,Immunology,Vaccine delivery,Immunotherapy, T cells, Severe malaria, inflammation, B cells, antibody responses,Quinine, malaria, Resistance, Chloroquine,4-aminoquinolone,Amodiaquine,Pyrimethamine,Proguanil, Mefloquine,Atovaquone,combination therapies, Primaquine , Artemisinin, Halofantrine,Doxycycline, Clindamycin, artemisinin, cryptolepine,traditional antimalarial plants, Antimalarial, Plasmodial control, prophylaxis, Polyphenols, Mefloquine derivatives, stereochemistry,antimalarial efficacy, dihydroartemisinin, combination, Antimalarial, Immune response, Therapy, Parasitostatic, Citrulline, Nitric Oxide, Severe Malaria, cerebral malaria, platelets, aspirin, plasmodium

This talk is part of the euroscicon series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity